Less Ads, More Data, More Tools Register for FREE

Pin to quick picksItaconix Plc Regulatory News (ITX)

Share Price Information for Itaconix Plc (ITX)

Share Price is delayed by 15 minutes
Get Live Data
110.00    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 6.00 (5.607%)
Market Cap: £14.83m
ITX Live PriceLast checked at - London Stock Exchange

Intraday Itaconix Plc Share Chart

Director/PDMR Shareholding

5 May 2015 07:01

RNS Number : 0960M
Revolymer PLC
05 May 2015
Β 

5 May 2015

Β 

Revolymer plc ("Revolymer" or "the Group")

Awards under Long Term Incentive Plan and other share awards

Β 

Revolymer (AIM: REVO) announces the grant of awards under the Revolymer plc Long Term Incentive Plan ("LTIP") and other share awards to its executive directors Kevin Matthews and Robin Cridland.

Β 

The LTIP was adopted by the board of directors of Revolymer plc (the "Board") on 29 June 2012 and its remuneration committee has approved the following grants on 30 April 2015:

Β· To the CEO Kevin Matthews a nil cost option over 567,568 ordinary shares

Β· To the CFO Robin Cridland a nil cost option over 349,550 ordinary shares.

Β 

The vesting period of these grants is three years and they only become exercisable if challenging performance conditions are met; namely that 50% of the grant becomes exercisable if the weighted average ordinary share price in the 180 day period ending on the third anniversary of grant is Β£0.75. Between weighted average ordinary share prices of Β£0.75 and Β£1.00, vesting shall be pro-rata and on a straight line basis between 50% and 100%. Below Β£0.75 the grants are not exercisable and lapse in full.

Β 

The Board also requires the executive directors to maintain minimum interests (of at least 420,000 ordinary shares for Kevin Matthews and 388,000 ordinary shares for Robin Cridland) before selling any ordinary shares that are the result of exercise, except that they may sell that number of ordinary shares that are required to satisfy any income tax and employee's national insurance liabilities arising at exercise. This requirement shall not apply on a change of control, or other transaction with substantially the same effect.

Β 

Also on 30 April 2015, the Board authorised the issue to Robin Cridland of 36,036 fully paid up ordinary shares in Revolymer plc ("New Shares") in recognition of his fulfilment of the role of Acting CEO during 2014 before the arrival of Kevin Matthews. Following the issue of the New Shares, Mr Cridland will hold 52,836 ordinary shares representing approximately 0.1% per cent. of the Company's issued share capital.

Β 

Application has been made to the London Stock Exchange for the 36,036 New Shares to be admitted to trading on AIM ("Admission"). Admission is expected to occur at 8:00 am on 8 May 2015. Following Admission, the total number of ordinary shares in the Company will be 56,597,176 with each Ordinary Share carrying the right to one vote. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in ACR under the FSA's Disclosure and Transparency Rules.

Β 

Ends

Β 

For further information please contact:

Revolymer plc

+44 (0) 1244 283 500

Kevin Matthews / Rob Cridland

Β 

Β 

Panmure Gordon (UK) Limited

+44 (0) 20 7886 2500

Hugh Morgan / Adam James (Corporate Finance)

Charles Leigh-Pemberton (Corporate Broking)

Β 

Β 

About Revolymer

Revolymer is an AIM quoted company (registered number 08024489) that designs, develops and formulates novel polymers to improve the performance of its customers' and partners' products.

The vision for Revolymer is to build a high growth, high quality margin, specialty materials business based on proprietary polymer technology that provides responsive or smart multi-functional materials. The Board believes that the Company's technology has broad application. Revolymer aims to generate growing high quality revenue streams by either licensing its proprietary technologies or through the supply of proprietary products using an outsourced manufacturing model. Current target markets are Household Products, Personal Care and Nicotine Gum.

www.revolymer.com

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
RDSEANSFEEXSEFF
Date   Source Headline
18th Apr 20177:00 amRNSNotice of AGM and Posting of Annual Report
4th Apr 20177:00 amRNSPreliminary Results Announcement - Replacement
27th Mar 20177:00 amRNSFinal Results
1st Mar 20177:00 amRNSChange of Name to Itaconix plc
10th Feb 20177:00 amRNSHolding(s) in Company
1st Feb 20171:33 pmRNSTotal Voting Rights
27th Jan 201711:53 amRNSJoint development agreement with AkzoNobel
23rd Jan 20177:00 amRNSExclusive Supply & Marketing Agreement with Croda
9th Jan 20177:00 amRNSBlock listing Interim Review
3rd Jan 20177:00 amRNSChange of Adviser
30th Dec 20169:22 amRNSDirectorate Change
2nd Nov 20161:18 pmRNSDivestment of Nicotine Gum Business
14th Oct 20167:00 amRNSDirector/PDMR Shareholding
6th Oct 20167:00 amRNSDirector/PDMR Shareholding
30th Sep 20167:00 amRNSDirector/PDMR Shareholding
22nd Sep 20167:00 amRNSInterim Results
19th Sep 20167:00 amRNSDivestment of Nicotine Gum Business
13th Sep 201611:34 amRNSDirectorate Change
7th Sep 20167:00 amRNSFirst Commercial Sales of Itaconix® CHTT
1st Aug 201611:33 amRNSTotal Voting Rights
15th Jul 20168:04 amRNSHolding(s) in Company
11th Jul 20164:34 pmRNSHolding(s) in Company
11th Jul 20163:35 pmRNSBlock listing Interim Review
8th Jul 201611:55 amRNSResult of General Meeting
8th Jul 20167:00 amRNSSuccessful Application for Accelerated Whitewash
22nd Jun 20164:29 pmRNSPosting of Circular and Notice of General Meeting
21st Jun 20162:24 pmRNSResults of Placing
21st Jun 20167:00 amRNSAcquisition & Placing
20th Jun 20165:31 pmRNSAcquisition & Placing
19th May 20162:33 pmRNSResult of AGM
19th May 20167:00 amRNSAGM Statement
7th Apr 20167:00 amRNSNotice of AGM & Posting of Annual Report
1st Apr 20167:00 amRNSTotal Voting Rights
21st Mar 20167:00 amRNSFinal Results
16th Mar 20167:00 amRNSDirectorate Change
1st Mar 20168:41 amRNSTotal Voting Rights
25th Jan 20167:00 amRNSRenewed & Expanded Contract
11th Jan 20167:00 amRNSBlocklisting Interim Review
30th Nov 20155:21 pmRNSHolding(s) in Company
30th Nov 20157:00 amRNSTotal Voting Rights
30th Oct 201512:30 pmRNSTotal Voting Rights
21st Sep 20157:00 amRNSInterim Results
18th Sep 20157:00 amRNSDirectorate Change
7th Sep 201512:18 pmRNSTotal Voting Rights
2nd Sep 20157:00 amRNSBlocklisting Interim Review
1st Sep 20157:03 amRNSLicence with OCI Alabama LLC
15th Jun 201512:27 pmRNSHolding(s) in Company
3rd Jun 20157:00 amRNSGlobal licence signed with Solvay
20th May 201512:17 pmRNSResult of AGM
15th May 20151:21 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.